Roanoke Asset Management Corp NY Purchases 1,883 Shares of Bristol-Myers Squibb (NYSE:BMY)

Roanoke Asset Management Corp NY grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,902 shares of the biopharmaceutical company’s stock after purchasing an additional 1,883 shares during the quarter. Roanoke Asset Management Corp NY’s holdings in Bristol-Myers Squibb were worth $3,275,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of BMY. Flputnam Investment Management Co. grew its holdings in shares of Bristol-Myers Squibb by 1.1% during the 4th quarter. Flputnam Investment Management Co. now owns 145,758 shares of the biopharmaceutical company’s stock valued at $8,244,000 after purchasing an additional 1,580 shares during the last quarter. Argyle Capital Management LLC boosted its position in Bristol-Myers Squibb by 3.9% during the fourth quarter. Argyle Capital Management LLC now owns 67,367 shares of the biopharmaceutical company’s stock valued at $3,810,000 after buying an additional 2,550 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Bristol-Myers Squibb by 13.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 17,506 shares of the biopharmaceutical company’s stock valued at $990,000 after buying an additional 2,030 shares during the last quarter. Wakefield Asset Management LLLP purchased a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $3,406,000. Finally, QRG Capital Management Inc. lifted its stake in shares of Bristol-Myers Squibb by 7.0% in the 4th quarter. QRG Capital Management Inc. now owns 309,565 shares of the biopharmaceutical company’s stock valued at $17,509,000 after acquiring an additional 20,177 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This represents a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Trading Up 1.5 %

BMY opened at $59.71 on Friday. The business has a 50 day moving average of $57.15 and a 200-day moving average of $54.70. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a market cap of $121.17 billion, a PE ratio of -13.51, a PEG ratio of 2.07 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.15%. The ex-dividend date of this dividend was Friday, January 3rd. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BMY. Wolfe Research started coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Truist Financial raised their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald upped their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Finally, Leerink Partnrs upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.